|
1
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar
|
|
3
|
Alberg AJ and Samet JM: Epidemiology of
lung cancer. Chest. 123:21S–49S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bourguignon LY, Wong G and Shiina M:
Up-regulation of histone methyltransferase, DOT1L, by matrix
hyaluronan promotes microRNA-10 expression leading to tumor cell
invasion and chemoresistance in cancer stem cells from head and
neck squamous cell carcinoma. J Biol Chem. 291:10571–10585. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Jin X, Zhang Q, Zhang G, Deng X and
Ma L: Decreased expression of miR-204 is associated with poor
prognosis in patients with breast cancer. Int J Clin Exp Pathol.
7:3287–3292. 2014.PubMed/NCBI
|
|
10
|
Ding M, Lin B, Li T, Liu Y, Li Y, Zhou X,
Miao M, Gu J, Pan H, Yang F, et al: A dual yet opposite
growth-regulating function of miR-204 and its target XRN1 in
prostate adenocarcinoma cells and neuroendocrine-like prostate
cancer cells. Oncotarget. 6:7686–7700. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan
H and Xu S: Decreased expression of miR-204 in plasma is associated
with a poor prognosis in patients with non-small cell lung cancer.
Int J Mol Med. 36:1720–1726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: MiR-204, down regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting CyclinD2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Liu XS, Liu HY, Lu YY and Li Y:
Reduced expression of serum miR-204 predicts poor prognosis of
gastric cancer. Genet Mol Res. 15:2016.
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H,
Xiao H, Qin H, Zhang C, Lü J, et al: A novel small molecule STAT3
inhibitor, LY5, inhibits cell viability, colony formation, and
migration of colon and liver cancer cells. Oncotarget.
7:12917–12926. 2016.PubMed/NCBI
|
|
16
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. National Academies Press;
Washington, DC: 1985
|
|
17
|
Wang Y, Zhao W and Fu Q: miR-335
suppresses migration and invasion by targeting ROCK1 in
osteosarcoma cells. Mol Cell Biochem. 384:105–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérol M, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski
CR, et al: Quality of life results from the phase 3 REVEL
randomized clinical trial of ramucirumab-plus-docetaxel versus
placebo-plus-docetaxel in advanced/metastatic non-small cell lung
cancer patients with progression after platinum-based chemotherapy.
Lung Cancer. 93:95–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lynam-Lennon N, Maher SG and Reynolds JV:
The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos
Soc. 84:55–71. 2009. View Article : Google Scholar
|
|
21
|
Slack FJ and Weidhaas JB: MicroRNA in
cancer prognosis. N Engl J Med. 2720–2722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han Z, Zhang Y, Sun Y, Chen J, Chang C,
Wang X and Yeh S: ERβ-mediated alteration of circATP2B1 and
miR-204-3p signaling promotes invasion of clear cell renal cell
carcinoma. Cancer Res. 2018.
|
|
23
|
Chung TK, Lau TS, Cheung TH, Yim SF, Lo
KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, et al: Dysregulation
of microRNA-204 mediates migration and invasion of endometrial
cancer by regulating FOXC1. Int J Cancer. 130:1036–1045. 2012.
View Article : Google Scholar
|
|
24
|
Butrym A, Rybka J, Baczyńska D, Tukiendorf
A, Kuliczkowski K and Mazur G: Low expression of microRNA-204
(miR-204) is associated with poor clinical outcome of acute myeloid
leukemia (AML) patients. J Exp Clin Cancer Res. 34:682015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Yin Y, Hu Y, Zhang J, Bian Z,
Song M, Hua D and Huang Z: MicroRNA-204-5p inhibits gastric cancer
cell proliferation by downregulating USP47 and RAB22A. Med Oncol.
32:3312015. View Article : Google Scholar
|
|
26
|
Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y,
Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration,
invasion and epithelial-mesenchymal transition in osteosarcoma
cells via targeting Sirtuin 1. Oncol Rep. 34:399–406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moldovan GL, Pfander B and Jentsch S:
PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stoimenov I and Helleday T: PCNA on the
crossroad of cancer. Biochem Soc Trans. 37:605–613. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Witko-Sarsat V, Mocek J, Bouayad D,
Tamassia N, Ribeil JA, Candalh C, Davezac N, Reuter N, Mouthon L,
Hermine O, et al: Proliferating cell nuclear antigen acts as a
cytoplasmic platform controlling human neutrophil survival. J Exp
Med. 207:2631–2645. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rosental B, Brusilovsky M, Hadad U, Oz D,
Appel MY, Afergan F, Yossef R, Rosenberg LA, Aharoni A, Cerwenka A,
et al: Proliferating cell nuclear antigen is a novel inhibitory
ligand for the natural cytotoxicity receptor NKp44. J Immunol.
187:5693–5702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nadauld LD, Garcia S, Natsoulis G, Bell
JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, et al:
Metastatic tumor evolution and organoid modeling implicate TGFBR2
as a cancer driver in diffuse gastric cancer. Genome Biol.
15:4282014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang SC: PCNA: A silent housekeeper or a
potential therapeutic target? Trends Pharmacol Sci. 35:178–186.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Chen T, Huang H, Jiang Y, Yang L,
Lin Z, He H, Liu T, Wu B, Chen J, et al: miR-363-3p inhibits tumor
growth by targeting PCNA in lung adenocarcinoma. Oncotarget.
8:20133–20144. 2017.PubMed/NCBI
|
|
34
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
